Progression, remission, regression of chronic renal diseases

Lancet

Volumn 357, Issue 9268, 2001, Pages 1601-1608

  Ruggenenti, Piero ^a   Schieppati, Arrigo ^a   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENZYME INHIBITOR; GLUCOSE; GLYCOSAMINOGLYCAN; LEPTIN; NIFEDIPINE; OMAPATRILAT; RAMIPRIL; UNCLASSIFIED DRUG; VASOPEPTIDASE INHIBITOR;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIALYSIS; DISEASE COURSE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY; KIDNEY INJURY; LIPID BLOOD LEVEL; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEINURIA; REMISSION; REVIEW; SMOKING CESSATION; TISSUE REPAIR;

EID: 0035912555     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04728-0     Document Type: Review

References (76)

1. Platt R. Structural and functional adaptation in renal failure. BMJ. 1:1952;1372-1377.
2. Brenner B.M., Meyer T.W., Hostetter T.H. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 307:1982;652-659.
3. Anon. The USRDS and its products. United States Renal Data System. Am J Kidney Dis 1998; 32 (suppl): S20-194.
4. Valderrabano F., Berthoux F.C., Jones E.H., Mehls O. Report on management of renal failure in Europe, XXV, 1994 end stage renal disease and dialysis report. The EDTA-ERA Registry. Nephrol Dial Transplant ; 11. 11:(Suppl):1996;2-21.
5. Collins A., Xue J.L., Ma J.Z., Louis T. Estimating the number of patients and medicare cost for end stage renal disease in the US to the year 2010. J Am Soc Nephrol. 11:2000;133A.
6. Rutkowski B. Changing pattern of end-stage renal diseasein central and eastern Europe. Nephrol Dial Transplant. 15:2000;156-160.
7. Remuzzi G., Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 339:1998;1448-1456.
8. Locatelli F., Alberti D., Graziani G., Buccianti G., Redaelli B., Giangrande A. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Lancet. 337:1991;1299-1304.
9. Klahr S., Levey A.S., Beck G.J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 330:1994;877-884.
10. Kasiske B.L., Lakatua J.D., Ma J.Z., Louis T.A. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 31:1998;954-961.
11. Anderson S., Rennke H.G., Brenner B.M. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 77:1986;1993-2000.
12. Zatz R., Dunn B.R., Meyer T.W., Anderson S., Rennke H.G., Brenner B.M. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 77:1986;1925-1930.
13. Mogensen C.E. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest. 36:1976;383-388.
14. Kasiske B.L., Kalil R.S., Ma J.Z., Liao M., Keane W.F. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 118:1993;129-138.
15. Klag M.J., Whelton P.K., Randall B.L., et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 334:1996;13-18.
16. Peterson J.C., Adler S., Burkart J.M., et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease study. Ann Intern Med. 123:1995;754-762.
17. Baigent C., Burbury K., Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 356:2000;147-152.
18. Parving H.-H., Osterby R., Anderson P.W., Hsueh W.A. Diabetic nephropathy. Brenner B.M. Brenner & Rector's. The kidney. 5th edn :1996;1864-1892 WB Saunders Company, Philadelphia.
19. Remuzzi A., Puntorieri S., Battaglia C., Bertani T., Remuzzi G. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest. 85:1990;541-549.
20. Rovin B.H., Tan L.C. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int. 43:1993;218-225.
21. Abbate M., Zoja C., Corna D., Capitanio M., Bertani T., Remuzzi G. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol. 9:1998;1213-1224.
22. Rossing P., Hommel E., Smidt U.M., Parving H.-H. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes. 42:1993;715-719.
23. Ruggenenti P., Perna A., Mosconi L., Pisoni R., Remuzzi G. Urinary protein excretion rate is the best independent predictor to ESRF in non-diabetic chronic nephropathies. Kidney Int. 53:1998;1209-1216.
24. Tarver-Carr M.E., Brancati F.L., Eberhardt M.S., Powe N.R. Proteinuria and the risk of chronic kidney disease (CKD) in the United States. J Am Soc Nephrol (abstr). 11:2000;168A.
25. Hoy WE, Wang Z, vanBuynder P, Baker PRA, McDonald SM, Mathews JD. The natural history of renal disease: Part 2 - the predictive value of albuminuria and glomerular filtration rate for natural death and renal failure community-based cohort of Australian Aborigines with high rates of renal disease. Kidney Int (in press).
26. Wapstra F.H., Navis G., de Jong P.E., de Zeeuw D. Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease. Exp Nephrol. 4:(Suppl):1996;47-52.
27. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 329:1993;1456-1462.
28. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 349:1997;1857-1863.
29. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia. 39:1996;587-593.
30. Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 355:2000;253-259.
31. Ruggenenti P., Perna A., Gherardi G., Gaspari F., Benini R., Remuzzi G. Renal function and requirement of dialysis in chronic nephropathy patients on long-term Ramipril: REIN follow-up trial. Lancet. 352:1998;1252-1256.
32. Hannedouche T., Landais P., Goldfarb B., et al. Randomised controlled trial of enalapril and β blockers in non-diabetic chronic renal failure. BMJ. 309:1994;833-837.
33. Maschio G., Alberti D., Janin G., et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 334:1996;939-945.
34. Jafar T.H., Schmid C.H., Stark P.C., et al. The optimal level of blood pressure and urine protein excretion for the prevention of progression of chronic renal disease. J Am Soc Nephrol (abstr). 11:2000;63A-64A.
35. Parving H.-H., Smidt U.M., Hommel E., et al. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis. 22:1993;188.
36. Wilmer W.A., Hebert L.A., Lewis E.J., et al. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the captopril study. Am J Kidney Dis. 34:1999;308-314.
37. Ruggenenti P., Perna A., Benini R., et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. J Am Soc Nephrol. 10:1999;997-1006.
38. Weidmann P., Schneider M., Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant. 10:(Suppl 9):1995;39-45.
39. Ruggenenti P., Perna A., Lesti M., et al. Pretreatment blood pressure reliably predicts progression of chronic nephropathies. Kidney Int. 58:2000;2093-2101.
40. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patientswith hypertension - principal results of the HypertensionOptimal Treatment (HOT) randomised trial. Lancet. 351:1998;1755-1762.
41. Somes G.W., Pahor M., Shorr R.I., Cushman W.C., Applegate W.B. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med. 159:1999;2004-2009.
42. Zoja C., Corna D., Facchinetti D., et al. Combining ACE inhibition and angiotensin II (AII) receptor blocking stop renal disease progression in experimental membranous nephropathy (MN). J Am Soc Nephrol (abstr). 6:1995;860.
43. Ors M., MacKenzie H.S., Troy J.L., Rennke H.G., Brenner B.M. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol. 9:1998;224-230.
44. Azizi M., Chatellier G., Guyene T.T., Murieta-Geoffroy D., Menard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation. 92:1995;825-834.
45. Zoccali C., Valvo E., Russo D., Panichi V., Zuccala A. Antiproteinuric effect of Losartan in patients with chronic renal diseases. Nephrol Dial Transplant. 12:1997;234-235.
46. Hovind P., Rossing P., Tarnow L., Toft H., Parving J., Parving H.-H. Remission of nephrotic range albuminuria in diabetic nephropathy. J Am Soc Nephrol (abstr). 11:2000;116A.
47. Russo D., Pisani A., Balletta M.M., et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis. 33:1999;851-856.
48. Bakris G.L., Weir M.R., De Quattro V., McMahon F.G. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 54:1998;1283-1289.
49. Griffin K.A., Picken M.M., Bidani A.K. Deleterious effects on calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest. 96:1995;798-800.
50. National institute of health. Drugs found to protect the kidneys. NIH News Release. Oct 13, 2000.
51. Moorhead J.F., Chan M.K., El-Nahas M., Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet. 2:1982;1309-1311.
52. Mulec H., Johnson S.A., Wiklund O., Björck S. Cholesterol: a renal risk factor in diabetic nephropathy. Am J Kidney Dis. 22:1993;196-201.
53. Keane W.F. Lipids and the kidney. Kidney Int. 46:1994;910-920.
54. Samuelsson O., Mulec H., Knight-Gibson C., et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant. 12:1997;1908-1915.
55. Fried L.F., Orchard T.J., Kasiske B.L., et al. Effects of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int. 59:2001;260-269.
56. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
57. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 47:1995;1703-1720.
58. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ. 311:1995;973-977.
59. Remuzzi G. Cigarette smoking and renal function impairment. Am J Kidney Dis. 33:1999;807-813.
60. Orth S.R., Ogata H., Ritz E. Smoking and the kidney. Nephrol Dial Transplant. 15:2000;1509-1511.
61. Orth S.R., Stockmann A., Conradt C., et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int. 54:1998;926-931.
62. Ruggenenti P, Brenner BM, Remuzzi G. Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. Nephron (in press).
63. Benigni A., Colosio V., Brena C., Bruzzi I., Bertani T., Remuzzi G. Unselective inhibition of endothelin receptorsreduces renal dysfunction in experimental diabetes. Diabetes. 47:1998;450-456.
64. Benigni A., Remuzzi G. Endothelin antagonists. Lancet. 353:1999;133-138.
65. Weber M. Vasopeptidase inhibitors. Lancet (in press).
66. Taal M.W., Nenov V.D., Satyal S.R., et al. Vasopeptidase inhibition affords greater renoprotection than ACE inhibition alone in rats with established nephropathy after 5/6 nephrectomy. J Am Soc Nephrol (abstr). 11:2000;631A.
67. Rouleau J.L., Pfeffer M.A., Stewart D.J., et al. Vasopeptidase inhibitor or angiotensin converting enzyme inhibitor in heart failure? Results of the IMPRESS trial. Circulation. 100:(suppl 1):1999;1-782.
68. Burnett J.C. Vasopeptidase inhibition. Curr Opin Nephrol Hypertens. 9:2000;465-468.
69. Wolf G., Panzer U., Stahl R.A.K. Regulatory peptides and their antagonists in nephropathies. Curr Opin Nephrol Hypertens. 9:2000;233-239.
70. Gambaro G., Baggio B. Glycosaminoglycans: a new paradigm in the prevention of proteinuria and progression of glomerular disease. Nephrol Dial Transplant. 11:1996;762-764.
71. Gambaro G., Manitius J., Pont'uch P., Skrha J. DiNAS group. Long-lasting reduction of albuminuria by oral sulodexide in micro- and macro-albuminuric type 1 and type 2 diabetic patients: The DiNAS. Trial. J Am Soc Nephrol (abstr). 11:2000;114A.
72. Ruggenenti P., Perna A., Zoccali C., et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. J Am Soc Nephrol. 11:2000;88-96.
73. Nakamura T., Takahashi T., Fukui M., et al. Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J Am Soc Nephrol. 5:1995;1492-1497.
74. Remuzzi A., Fassi A., Bertani T., Perico N., Remuzzi G. ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. Am J Kidney Dis. 34:1999;626-632.
75. Fogo A.B. Progression and potential regression of glomerulosclerosis. Kidney Int. 59:2001;804-819.
76. Nakamura S., Nakamura I., Ma L., Fogo A. Regression of established glomerulosclerosis by high dose angiotensin type 1 receptor antagonist (AIIRA) is linked to inhibition of plasminogen activator inhibitor-1 (PAI-1). J Am Soc Nephrol (abstr). 10:1999;665A.